trial

Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

NCTId NCT01121042
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 85 (actual)
Sponsored by Bayside Health
Primary completion 2018-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
85 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-07
Primary completion
2018-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ondansetron

Sponsors

Bayside HealthLead Sponsor

Investigators

1
Professor Jayashri KulkarniPrincipal Investigator

Sites

1 total
Melbourne, Australia

Linked catalysts

1
Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Sch — primary completion2018-08

Facts & assertions

4 sourced
Enrollment
85
Phase
PHASE3
Primary Completion Date
2018-08
Status
COMPLETED
relationships
The graph out of here
drug
ondansetron
drug
lead_sponsor
Bayside Health
company
indication
Schizoaffective and Schizophreniform Disorders
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Professor Jayashri Kulkarni
person